Nurix Therapeutics, Inc. NRIX
We take great care to ensure that the data presented and summarized in this overview for Nurix Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NRIX
View all-
Black Rock Inc. New York, NY6.82MShares$153 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.28MShares$95.8 Million6.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.01MShares$89.7 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$86.8 Million0.93% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.87MShares$86.5 Million3.2% of portfolio
-
Wellington Management Group LLP Boston, MA3.48MShares$77.9 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.07MShares$68.7 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD2.55MShares$57 Million0.03% of portfolio
-
State Street Corp Boston, MA2.37MShares$53 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl2.22MShares$49.6 Million0.47% of portfolio
Latest Institutional Activity in NRIX
Top Purchases
Top Sells
About NRIX
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
Insider Transactions at NRIX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 04
2024
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,290
-10.49%
|
$82,250
$25.0 P/Share
|
|
Nov 04
2024
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,290
+9.49%
|
$29,610
$9.57 P/Share
|
|
Nov 01
2024
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,546
-9.51%
|
$85,104
$24.28 P/Share
|
|
Nov 01
2024
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,760
-17.02%
|
$138,240
$24.28 P/Share
|
|
Nov 01
2024
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,760
+14.54%
|
$5,760
$1.86 P/Share
|
|
Oct 30
2024
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,182
-12.96%
|
$100,368
$24.3 P/Share
|
|
Oct 30
2024
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,674
+7.91%
|
-
|
|
Oct 30
2024
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,437
-6.35%
|
$82,488
$24.3 P/Share
|
|
Oct 30
2024
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,957
+5.51%
|
-
|
|
Oct 30
2024
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,368
-5.97%
|
$56,832
$24.3 P/Share
|
|
Oct 30
2024
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,636
+7.26%
|
-
|
|
Oct 14
2024
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,290
-11.8%
|
$82,250
$25.0 P/Share
|
|
Oct 14
2024
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,290
+10.55%
|
$29,610
$9.57 P/Share
|
|
Oct 01
2024
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,760
-9.6%
|
$126,720
$22.5 P/Share
|
|
Oct 01
2024
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,760
+15.95%
|
$5,760
$1.86 P/Share
|
|
Sep 03
2024
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
9,050
-13.56%
|
$226,250
$25.28 P/Share
|
|
Sep 03
2024
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,050
+12.43%
|
$45,250
$5.72 P/Share
|
|
Aug 26
2024
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
9,870
-28.64%
|
$246,750
$25.01 P/Share
|
|
Aug 26
2024
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,870
+13.44%
|
$49,350
$5.72 P/Share
|
|
Aug 26
2024
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
20,000
-39.21%
|
$500,000
$25.22 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 133K shares |
|---|
| Open market or private sale | 156K shares |
|---|---|
| Bona fide gift | 54K shares |